Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Harbaum, L; Olschewski, H; Klose, H.
Pharmacotherapy of pulmonary arterial hypertension
PNEUMOLOGE. 2015; 12(5): 390-400.
Doi: 10.1007/s10405-015-0881-5
Web of Science
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Olschewski Horst
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The pharmaceutical treatment of pulmonary arterial hypertension (PAH) has been the subject of continuous development over the last years. A growing number of targeted therapies are available as well as new evidence for the implementation of supportive therapy. Evidence for the use of targeted therapies comes from larger controlled trials. Treatment should be guided in a structured manner by predefined treatment goals. A repeated evaluation of the treatment response and tolerability is mandatory. In the case of an unsatisfactory response the treatment algorithm recommends combination therapy and if necessary lung transplantation. The targeted therapies consist of calcium channel blockers, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators and prostanoids. Supportive therapy comprises optimization and modulation of anticoagulation, diuretics, antiarrhythmic therapy and antidepressive treatment. The current treatment results in a reduction of morbidity and improvement of event-free survival.
- Find related publications in this database (Keywords)
- Pharmacotherapy
- Treatment response
- Combination therapy
- Targeted therapy
- Morbidity